Hot Flashes

 

Hot flashes are caused by hormonal changes that interfere with your body’s ability to lower its temperature. If you’ve been treated for breast cancer or prostate cancer, your hormone levels have been affected, and there is a good chance that you will experience hot flashes at some point.

You’ll know you are having a hot flash because your face and upper body will get hot, red, and sweaty. Your heart will beat faster, dilating your blood vessels. This circulates more blood, which causes more heat. Your sweat glands then give off more perspiration in an effort to cool your body.

Sometimes chemotherapy causes sudden menopause (known as chemotherapy-induced menopause). This can bring on hot flashes. In addition, hormonal treatment of breast cancer with drugs, including tamoxifen, Arimidex® (anastrozole), or Femara® (letrozole) can also cause hot flashes. Men who are being treated with hormonal therapy for prostate cancer can also experience hot flashes. Lupron® and Eligard® (leuprolide), Zoladex® (goserelin), Trelstar® (triptorelin pamoate), and Vantas (histrelin)® are hormone-blocking medications that can cause hot flashes.

Tips for Managing Hot Flashes

  • Dress in layers of cotton clothing—daytime clothing and sleepwear.
  • Keep your home or workplace at a cool temperature.
  • Keep ice water handy.
  • Take a cool shower.
  • Try deep-breathing exercises.
  • Consider acupuncture or yoga.
  • Talk to your doctor about the medications Neurontin® (gabapentin), Effexor-XR® (venlafaxine), or Paxil® (paroxetine), or other drugs in the family of agents called SSRIs.
This content was last modified on February 08, 2008 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health